Sarclisa

Chemical Nameisatuximab
Dosage FormInjection (intravenous; 100 mg/5 mL, 500 mg/25 mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanySanofi-Aventis
Approval Year2020

Indication

  • Indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Last updated on 12/7/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sarclisa (isatuximab) Prescribing Information.2020Sanofi-Aventis U.S. LLC, Bridgewater, NJ